Number of the records: 1
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours
- 1.
SYSNO ASEP 0024471 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours Title Chemoterapie, genová terapie IL-12 a kombinovaná adjuvantní terapie MHC I+ a MHC I- nádorů vyvolaných HP 16 Author(s) Indrová, Marie (UMG-J) RID
Bieblová, Jana (UMG-J)
Jandlová, Táňa (UMG-J)
Vonka, V. (CZ)
Pajtasz-Piasecka, E. (PL)
Reiniš, Milan (UMG-J) RIDSource Title International Journal of Oncology. - : Spandidos Publications - ISSN 1019-6439
Roč. 28, č. 1 (2006), s. 253-260Number of pages 8 s. Language eng - English Country GR - Greece Keywords HPV16 ; MHC class I-deficient and MHC class I-proficient tumour cells ; CMRTD Subject RIV EC - Immunology R&D Projects NR7807 GA MZd - Ministry of Health (MZ) NR8004 GA MZd - Ministry of Health (MZ) CEZ AV0Z50520514 - UMG-J (2005-2011) Annotation Moderately immunogenic HPV 16-associated tumour cell line mimicking human HPV 16-associated neoplasms TC-1 (MHC class I+) and its variants with a marked downregulation of MHC I molecules were used to examine the effect of local IL-12 gene therapy for the treatment of early tumour transplants and minimal residual tumour disease obtained after cytoreductive chemotherapy (CMRTD). The results indicate that the MHC I phenotype is not stable during tumour progression and treatment and they illustrate the efficacy of IL-12 gene therapy in combination with chemotherapy on HPV 16-associated tumours regardless of the level of MHC class I expression on the tumour cells. Workplace Institute of Molecular Genetics Contact Nikol Škňouřilová, nikol.sknourilova@img.cas.cz, Tel.: 241 063 217 Year of Publishing 2006
Number of the records: 1